Tissue Regenix Group
Leeds, United Kingdom

Tissue Regenix is a regenerative medicine company with a portfolio of soft tissue and bone products and two proprietary platform, dCELL, and BioRinse. Applications include wound care/general surgery, orthopaedics, sports medicine, and dental care. Commercialisation of the leading products are underway.


Investment Perspective

Tissue Regenix Group grew underlying revenues by 47% to £11.6m, ahead of our forecasts. This was achieved through the efficient integration of CellRight Technologies and the benefits of the new commercialisation strategy. Tissue Regenix now has a more focused direct marketing approach and is leveraging the return on its research and manufacturing capabilities by entering into strategic partnerships, such as those signed with ARMS Medical and Arthrex, Inc. These new relationships should sustain the strong growth of Tissue Regenix. Our valuation is unchanged for now at 20.9p/share.

Market information

Symbol Primary exchange Currency
Last Price Market Cap
52 Week Low 52 Week High


New strategy delivering results
Update | 04 Feb 2019
Arthrex collaboration extended into Europe
Update | 13 Nov 2018
Executing the plan
Update | 03 Sep 2018

Recent News

Trading update
04 Feb 2019
Interim management change
05 Dec 2018
Pan-European distribution agreement with Arthrex
13 Nov 2018
H118 interim results
03 Sep 2018